Translational Research in Maternal and Pediatric Pharmacology and Therapeutics (R21 Clinical Trial Optional)
ID: 346551Type: Posted
Overview

Buyer

National Institutes of Health (HHS-NIH11)

Award Range

$0 - $225K

Eligible Applicants

Others

Funding Category

Income Security and Social Services

Funding Instrument

Grant

Opportunity Category

Discretionary

Cost Sharing or Matching Requirement

Yes

Original Source

https://grants.gov/search-results-detail/346551

Additional Information

http://grants.nih.gov/grants/guide/pa-files/PAR-23-131.html
Timeline
    Description

    The National Institutes of Health (NIH) is offering a funding opportunity titled "Translational Research in Maternal and Pediatric Pharmacology and Therapeutics (R21 Clinical Trial Optional)" aimed at enhancing research in maternal and pediatric pharmacology. This grant supports translational and clinical research focused on advancing precision medicine for pregnant individuals, lactating persons, and children, as well as understanding drug action mechanisms and developing safer therapeutics for these populations. The initiative is crucial for improving healthcare outcomes for underrepresented groups, with a funding ceiling of $275,000 available over two years. Interested applicants, including various educational and research institutions, must submit their proposals by May 7, 2026, and can find more information at the NIH grants website or contact grantsinfo@nih.gov for inquiries.

    Point(s) of Contact
    grantsinfo@nih.gov
    Files
    Title
    Posted
    PAR-23-131-Full-Announcement.html
    PAR-23-131.html
    The Department of Health and Human Services' funding opportunity aims to enhance maternal and pediatric pharmacology through the R21 Exploratory/Developmental Research Grant. It supports research in three main areas: advancing precision medicine for pregnant individuals and children, understanding drug action mechanisms during pregnancy and lactation, and developing safer therapeutics for these populations. The initiative is spearheaded by the National Institutes of Health, with participation from specific institutes focusing on child health, allergy, and drug abuse. Key objectives include creating innovative tools and methodologies for clinical impact, as well as fostering research into pharmacokinetics to develop safer drug applications. The grant is open for applications until May 2026, offering up to $275,000 in direct costs over two years. Eligible applicants include various educational and research institutions, with an emphasis on interdisciplinary collaboration. The announcement highlights the need for adherence to rigorous application instructions and encourages the sharing of research findings to expand scientific knowledge and improve healthcare outcomes for these underrepresented populations.
    Similar Opportunities
    Translational Research in Maternal and Pediatric Pharmacology and Therapeutics (R01 Clinical Trial Optional)
    Active
    National Institutes of Health
    The National Institutes of Health (NIH) is offering a funding opportunity titled "Translational Research in Maternal and Pediatric Pharmacology and Therapeutics (R01 Clinical Trial Optional)" aimed at advancing precision medicine for pregnant individuals, lactating persons, and children. This grant seeks to support translational and clinical research that develops novel tools and methodologies to enhance the understanding of drug action mechanisms and improve the safety and effectiveness of therapeutics for these populations. The initiative is crucial for addressing critical gaps in healthcare for vulnerable groups, with a focus on discovering safer medications and utilizing innovative approaches such as machine learning for precision dosing. Interested applicants can find more information and submit proposals by May 7, 2026, and should direct inquiries to NIH Grants Information at grantsinfo@nih.gov.
    Advancing Methods for Safe, Noninvasive, Real Time Assessment of Placenta Development and Function Across Pregnancy (R21 Clinical Trial Not Allowed)
    Active
    National Institutes of Health
    The National Institutes of Health (NIH) is offering a funding opportunity titled "Advancing Methods for Safe, Noninvasive, Real Time Assessment of Placenta Development and Function Across Pregnancy" under the R21 grant mechanism. This initiative aims to support the development and clinical validation of innovative, non-invasive methods to assess placental health throughout pregnancy, addressing critical issues such as preeclampsia and fetal growth restrictions. The funding, capped at $275,000 over a two-year period, is open to a diverse range of eligible applicants, including higher education institutions, nonprofit organizations, and tribal governments, with a submission deadline of November 16, 2024. Interested parties can find more information and contact NIH Grants Information at grantsinfo@nih.gov for inquiries.
    Advancing Research to Understand Congenital Malformations (R01 Clinical Trial Not Allowed)
    Active
    National Institutes of Health
    The National Institutes of Health (NIH) is offering a funding opportunity titled "Advancing Research to Understand Congenital Malformations (R01 Clinical Trial Not Allowed)" aimed at supporting innovative research into the mechanisms underlying structural birth defects. This grant encourages applicants to utilize animal models alongside human translational and clinical approaches, focusing on genetic, epigenetic, and environmental factors that contribute to these conditions. With over 120,000 infants affected annually in the U.S., this research is critical for public health, and projects may receive funding of up to $499,999 per year for a maximum of five years. Interested applicants must submit their proposals by September 7, 2025, and can direct inquiries to NIH Grants Information at grantsinfo@nih.gov or visit the opportunity's webpage for more details at https://grants.nih.gov/grants/guide/pa-files/PAR-22-215.html.
    NIH Exploratory/Developmental Research Grant Program (Parent R21 Clinical Trial Required)
    Active
    National Institutes of Health
    The National Institutes of Health (NIH) is offering the Exploratory/Developmental Research Grant Program (Parent R21 Clinical Trial Required) to support innovative research projects at the preliminary or conceptual stage, particularly those with the potential to advance biomedical, behavioral, or clinical research. Applicants must include at least one clinical trial in their proposals, focusing on mechanistic studies that align with the scientific missions of participating NIH Institutes and Centers. This funding opportunity is crucial for stimulating novel research that challenges conventional methods and improves clinical practices, with a maximum budget of $275,000 available for a two-year project, and no more than $200,000 allocated in any single year. Interested applicants should adhere to strict submission guidelines and can contact the NIH OER Webmaster at FBOWebmaster@OD.NIH.GOV for assistance; the application deadline is January 7, 2025.
    Multisite Clinical Research: Leveraging Network Infrastructure to Advance Research for Women, Children, Pregnant and Lactating Individuals, and Persons with Disabilities (U01 Clinical Trial Optional)
    Active
    National Institutes of Health
    The National Institutes of Health (NIH) has announced a funding opportunity (PAR-23-037) aimed at promoting multisite clinical trials and observational studies focused on women, children, pregnant and lactating individuals, and persons with disabilities. The initiative seeks to enhance the rigor and reproducibility of clinical trial protocols, facilitate data sharing, and increase the involvement of diverse populations in research through the utilization of NICHD-supported Network infrastructure. This funding opportunity supports projects for up to five years, with budgets reflecting actual needs, and requires a rigorous pre-application process starting with a Letter of Inquiry. Interested applicants can find more information and submit inquiries via grantsinfo@nih.gov, with ongoing application cycles and a close date set for May 7, 2026.
    Innovative Screening Approaches and Therapies for Screenable Disorders in Newborns (R21 - Clinical Trial Optional)
    Active
    National Institutes of Health
    The National Institutes of Health (NIH) has announced a funding opportunity for innovative research aimed at developing screening approaches and therapies for screenable disorders in newborns, designated as R21 - Clinical Trial Optional. This initiative encourages projects that focus on creating novel screening techniques and therapeutic interventions for potentially fatal or disabling conditions identified through newborn screening, particularly emphasizing early diagnosis and treatment to improve health outcomes. The program is part of NIH's commitment to advancing public health and reducing health disparities, with a funding ceiling of $275,000 available over a two-year period. Interested applicants, including a diverse range of institutions and organizations, must submit their proposals by November 16, 2024, and can reach out to the NIH OER Webmaster at OERWebmaster03@od.nih.gov for further inquiries.
    Effect of HIV and Substance Use Comorbidity on the Placenta and Maternal Outcomes (R01 Clinical Trial Optional)
    Active
    National Institutes of Health
    The National Institutes of Health (NIH) is offering a funding opportunity titled "Effect of HIV and Substance Use Comorbidity on the Placenta and Maternal Outcomes (R01 Clinical Trial Optional)" aimed at investigating the interactions between HIV, antiretroviral therapy (ART), and substance use during pregnancy. This initiative seeks to enhance understanding of placental health and its implications for maternal and fetal outcomes, particularly focusing on the pathophysiology of placental abnormalities in the context of substance misuse. The NIH plans to allocate up to $2 million for fiscal year 2025 to support 2-5 research project grants, with applications opening on October 15, 2024, and a submission deadline of November 15, 2024. Interested applicants can find more information and guidelines at the NIH grants website or contact NIH Grants Information at grantsinfo@nih.gov for inquiries.
    NIH Exploratory/Developmental Research Grant Program (Parent R21 Clinical Trial Not Allowed)
    Active
    National Institutes of Health
    The National Institutes of Health (NIH) is offering the Exploratory/Developmental Research Grant Program (Parent R21 Clinical Trial Not Allowed) to support innovative biomedical and clinical research projects. This grant aims to foster exploratory research that may involve significant risks but has the potential for breakthroughs or the development of novel methodologies in health-related fields. The program is crucial for advancing research that addresses pressing health challenges and encourages applications that present new scientific ideas distinct from traditional R01 projects. Eligible applicants include a wide range of institutions, including higher education institutions, nonprofits, and for-profit organizations, both domestic and foreign, with a budget limit of $275,000 over two years and a maximum request of $200,000 in any single year. Interested parties should submit their applications electronically by January 7, 2025, and can contact the NIH OER Webmaster at FBOWebmaster@OD.NIH.GOV for further assistance.
    NICHD Small Research Grant Program (R03 Clinical Trial Required)
    Active
    National Institutes of Health
    The National Institutes of Health (NIH) is offering the NICHD Small Research Grant Program (R03 Clinical Trial Required) to support clinical trials that align with the mission of the Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD). This grant program is designed to fund small research projects with a maximum budget of $50,000 in direct costs per year, for a duration of up to two years, focusing on areas such as human development, childhood development, and rehabilitation medicine. Eligible applicants include a diverse range of organizations, including higher education institutions, nonprofits, for-profits, and tribal governments, with all applications required to propose clinical trials and adhere to NIH submission guidelines. Interested parties should note that the application deadline is January 7, 2025, and can reach out to the NIH OER Webmaster at grantsinfo@nih.gov for further inquiries. More information can be found at the provided link: http://grants.nih.gov/grants/guide/pa-files/PA-21-221.html.
    NCI Clinical and Translational Exploratory/Developmental Studies (R21 Clinical Trial Optional)
    Active
    National Institutes of Health
    The National Institutes of Health (NIH) is offering a funding opportunity through the R21 Clinical Trial Optional mechanism, aimed at supporting exploratory and developmental research in cancer diagnosis, treatment, imaging, symptom management, and prevention. This grant is designed to encourage innovative studies that challenge existing paradigms and address critical barriers in cancer research, particularly focusing on reducing disparities among underserved populations. Eligible applicants include a wide range of organizations, such as historically black colleges, tribal governments, and faith-based organizations, with a maximum funding amount of $275,000 available over a two-year period. Interested parties can find more information and application details at the provided link, with a submission deadline of July 1, 2025, and inquiries directed to the NIH OER Webmaster at OERWebmaster03@od.nih.gov.